Potassium%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to treat and prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. ## Adult Dosing * **Oral:** * **Prevention:** 20 mEq (1.5 g) per day, divided into 1-2 doses. * **Treatment:** 40-100 mEq (3-7.5 g) per day, divided into 2-4 doses. * Maximum single oral dose: Generally considered 20 mEq (1.5 g) per dose to minimize GI upset. * Maximum daily oral dose: Typically capped at 100-120 mEq (7.5-9 g) but may be higher under close medical supervision. * **Intravenous (IV):** * **Mild Hypokalemia (serum K+ 3.0-3.4 mEq/L):** 20 mEq (1.5 g) infused over 1-2 hours. * **Moderate Hypokalemia (serum K+ 2.5-2.9 mEq/L):** 40 mEq (3 g) infused over 2-4 hours. * **Severe Hypokalemia (serum K+ < 2.5 mEq/L) or ECG changes:** 40-100 mEq (3-7.5 g) or more, administered cautiously, often as a continuous infusion or in divided doses, depending on local protocol and patient response. * **Maximum IV infusion rate:** * Peripheral line: Typically limited to 10-20 mEq/hour (0.75-1.5 g/hour). Rates >10 mEq/hour can cause pain and phlebitis. * Central line: Rates up to 40 mEq/hour (3 g/hour) may be used in severe, symptomatic hypokalemia, with continuous ECG monitoring. Rates >20 mEq/hour require central access. * **Maximum concentration:** Peripheral lines: Typically 40 mEq/L (3 g/L). Central lines: May be higher, up to 80-100 mEq/L (6-7.5 g/L), as per institutional policy. ## Pediatric Dosing * Dosing is weight-based and depends on the severity of hypokalemia. **Refer to institutional protocols or specialized pediatric resources.** * General guidelines: * **Maintenance:** 1-2 mEq/kg/day orally. * **Repletion:** Up to 3-4 mEq/kg/day orally or IV, divided into doses. * **IV infusion rates:** Generally do not exceed 0.3-0.5 mEq/kg/hour. Higher rates may be considered in critical situations with continuous cardiac monitoring. * **Maximum IV concentration:** Typically 40 mEq/L (3 g/L). ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Potassium accumulation can occur. Lower doses and frequent monitoring are necessary. Avoid use in severe renal insufficiency if possible. ## Contraindications * Hyperkalemia. * Conditions that predispose to hyperkalemia, such as severe renal impairment or uncontrolled adrenal insufficiency. * Certain cardiac conditions where potassium may exacerbate arrhythmias. ## Adverse Effects * **Common:** Gastrointestinal upset (nausea, vomiting, diarrhea, abdominal pain) with oral formulations. Pain and phlebitis at IV infusion site. * **Serious:** Hyperkalemia (manifesting as cardiac arrhythmias, ECG changes, muscle weakness, paresthesias, paralysis), cardiac arrest. Esophageal or gastric ulceration/perforation with oral formulations, especially if taken with insufficient fluid or in patients with delayed gastric emptying. ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors and ARBs:** Can increase serum potassium levels, especially in patients with renal impairment. * **NSAIDs:** May reduce the potassium-excreting effect of the kidneys, increasing risk of hyperkalemia. * **Digitalis glycosides:** Hyperkalemia can increase the toxicity of digitalis. Hypokalemia can also potentiate digitalis toxicity. * **Cyclosporine:** Increased risk of hyperkalemia. ## Monitoring * **Serum potassium levels:** Frequently, especially during IV therapy, dose adjustments, or in patients with renal impairment. * **Renal function (BUN, creatinine):** Assess baseline and periodically. * **ECG:** Especially during rapid IV infusion or in patients with severe hypokalemia or risk factors for arrhythmias. * **Signs and symptoms of hyperkalemia and hypokalemia.** * **Fluid balance.** ## Clinical Pearls * Oral KCl formulations can be irritating to the GI tract. Advise patients to take with a full glass of water or juice and to avoid lying down immediately after taking. * Liquid formulations may be preferred for patients with difficulty swallowing tablets or capsules. * Rapid IV infusion of KCl can be dangerous and potentially fatal due to the risk of cardiac arrest from hyperkalemia. Always adhere to recommended infusion rates and concentrations. * In patients with severe hypokalemia, correction may take time, and gradual replacement is often preferred. * Always ensure the correct formulation (oral vs. IV) and concentration are used. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines before administering any medication. Patient-specific factors must be considered in all treatment decisions.